Clearside Biomedical
CLSD
CLSD was delisted on the 28th of November, 2025.
53 hedge funds and large institutions have $10.2M invested in Clearside Biomedical in 2022 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 9 increasing their positions, 15 reducing their positions, and 12 closing their positions.
288% more call options, than puts
Call options by funds: $229K | Put options by funds: $59K
0% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 12
0.33% less ownership
Funds ownership: 1.34% → 1.01% (-0.33%)
2% less funds holding
Funds holding: 54 → 53 (-1)
25% less capital invested
Capital invested by funds: $13.6M → $10.2M (-$3.39M)
40% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 15
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JJ
Johnson & Johnson
New Brunswick,
New Jersey
|
+$204K |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
+$127K |
| 3 |
HLA
Hamilton Lane Advisors
Conshohocken,
Pennsylvania
|
+$78.5K |
| 4 |
E
Ergoteles
New York
|
+$65.9K |
| 5 |
B
Bailard
Foster City,
California
|
+$57.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$469K |
| 2 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$292K |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$173K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$140K |
| 5 |
Millennium Management
New York
|
-$127K |
CLSD Hedge Fund Activity: Q4 2022 in Review
53 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Clearside Biomedical (CLSD) for Q4 2022, worth a combined $10.2M — down 25% from $13.6M a quarter earlier.
Fund positioning in CLSD was balanced in Q4 2022: 12 funds opened new positions, 12 closed out, 9 added to existing stakes and 15 trimmed.
The largest buyer was Johnson & Johnson, opening a new position worth an estimated $204K. The largest seller was BlackRock, cutting an estimated $469K.
- 53 institutional investors held Clearside Biomedical (CLSD) as of Q4 2022, down from 54 in Q3 2022.
- Funds reported $10.2M of Clearside Biomedical stock for Q4 2022, down 25% quarter-over-quarter.
- 12 funds opened new Clearside Biomedical positions in Q4 2022 and 12 closed out, a net change of 0 holders.
- The largest Clearside Biomedical buyer in Q4 2022 was Johnson & Johnson, an estimated $204K added.
- The largest Clearside Biomedical seller in Q4 2022 was BlackRock, an estimated $469K sold.
Based on aggregated 13F filings for Q4 2022.